The Latest Breaking News from Abbott Laboratories

The U.S. faced a nationwide shortage of the most popular baby formula brands in the week starting April 24, according to the latest figures from Datasembly, which tracks out-of-stock messages on retailers' websites and apps. An average rate is less than 10%. Reasons For The Shortage: Supply chain issues caused by the COVID-19…

Since the persistent Ukraine-Russia war, rising inflationary pressures, and Fed's upcoming interest rate hikes are expected to keep the stock market volatile in the near term, investors seek opportunities to invest in large-cap stocks, which hold the potential to generate relatively stable returns. So, we think it could be wise…

  Abbott Laboratories (NYSE:ABT) reported its Q1 earnings results on Wednesday, April 20, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 5 years by 8.67% on an annualized basis producing an average annual return of 21.94%. Currently, Abbott Laboratories has a market capitalization of $209.78 billion.

Abbott Laboratories (NYSE:ABT) is set to give its latest quarterly earnings report on Wednesday, 2022-04-20. Here's what investors need to know before the announcement. Analysts estimate that Abbott Laboratories will report an earnings per share (EPS) of $1.47.

The medical devices industry is thriving and the integration of advanced technologies position the industry well for growth. Therefore, prominent players in this space, Abbott Laboratories (ABT) and Zimmer Biomet Holdings (ZBH), should benefit. But which of these stocks is a better buy now? Read more to find out.

Raymond James has outlined its expectations for next week when Johnson & Johnson (NYSE:JNJ), Abbott Laboratories (NYSE:ABT), and Intuitive Surgical Inc (NASDAQ:ISRG) will report Q1 FY22 earnings. Analysts believe that the Med Tech investors have become somewhat 'paralyzed' given the macro/factor-driven concerns.  On the macro, investor attention seems to be focused less on revenue growth and more…

Abbott Laboratories's (NYSE:ABT) short percent of float has risen 28.81% since its last report. The company recently reported that it has 13.33 million shares sold short, which is 0.76% of all regular shares that are available for trading.

Eton Pharmaceuticals Inc (NASDAQ:ETON) has appointed James Gruber as Chief Financial Officer effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through May to ensure a smooth transition. Mr. Gruber, most recently, was the U.S. Controller at Horizon Therapeutics (NASDAQ:HZNP) for seven years, where he oversaw…